

Beating the odds: BETs in disease

Chen-Yi Wang¹ and Panagis Filippakopoulos^{1,2,*}

¹ Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.

² Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.

BETs, transcription, cancer, inflammation, viral infection, small molecule inhibitor

*To whom correspondence should be addressed: panagis.filippakopoulos@sgc.ox.ac.uk,
Telephone: +44 (0) 1865 617759, Fax: +44 (0) 1865 617575

Abstract

Bromodomains (BRDs) are evolutionarily conserved protein interaction modules that specifically recognize acetyl-lysine on histones and other proteins, facilitating roles in regulating gene transcription. BRD-containing proteins bound to chromatin loci such as enhancers are often deregulated in disease leading to aberrant expression of pro-inflammatory cytokines and growth promoting genes. Recent developments targeting the bromo and extra-terminal (BET) subset of BRD proteins demonstrated remarkable efficacy in murine models providing a compelling rationale for drug development and translation to the clinic. Here we summarize recent advances in our understanding of the role(s) of BETs in regulating gene transcription in normal and diseased tissue as well as the current status of their clinical translation.

Introduction: recognition of acetylated lysine

Lysine acetylation (Kac) is a regulatory post translational modification that, in the context of chromatin biology, is associated with open chromatin structure and transcriptional stimulation. Deregulation of acetylation levels has long been associated with disease, and the enzymes responsible for the removal of this modification (histone deacetylases, HDACs) have been successfully targeted in the past decade, resulting in approved drugs. However, it was only recently recognized that the protein domains that read acetyl-lysine—the evolutionarily conserved protein-protein interaction modules of the bromodomain (BRD) class [1]—can also be targeted. The bromo and extra-terminal class (BET) of the bromodomain family in particular has attracted a lot of attention following the disclosure of highly potent and selective inhibitors that attenuate BET function [2], which stimulated research that evaluated their biological role(s) and deregulation in disease. Here we review recent advancements in our understanding of BET proteins, their structural organization and their involvement in disease as well as the translation of their small molecule inhibitors to the clinic.

Architecture of BET proteins

BET proteins (BRD2, BRD3, BRD4 and the testis specific BRDT) have a conserved modular architecture, including two N-terminal tandem bromodomain effector modules (BRDs), an extra-terminal recruitment domain (ET), several conserved motifs (A,B, SEED motifs) and, in the case of BRD4 and BRDT, a C-terminal motif (**Figure 1A**). The bromodomain module is shared by a conserved family of 42 proteins (in human) that contains a total of 61 BRDs, including the eight BET BRDs (two per BET protein). Large scale structural analysis of the human BRD family offered insight into their conserved architecture, consisting of a four-helix bundle (helices αZ , αA , αB and αC) linked by diverse loop regions (ZA- and BC-loops) (**Figure 1B**) [1]. A conserved region of 12 amino acids (KGVK~~R~~KADTTTP, found at the end of the 'A' motif) between the two BET BRD modules was recently shown to act as a nuclear localization signal, and its deletion results in mislocalization of the mutant proteins in HEK293T cells [3]. In addition, the conserved

'B' motif is thought to be responsible for homo- and hetero-dimerization, at least in the case of BRD2, and its deletion results in dissociation from mitotic chromosomes [4]. The extra-terminal domain shared between the four BET proteins also exhibits a helical architecture (**Figure 1C**), including an acidic surface shaped in a continuous ridge [5] and has been shown to participate in protein:protein interactions [6]. Although no structural information has been obtained for a complete C-terminal motif (CTM) of BRD4/T, a complex structure of the human papillomavirus E2 protein was characterized bound to a short peptide portion of the BRD4 CTM [7], demonstrating that the C-terminal tail binds to a highly basic region of the viral protein (**Figure 1D**). In the last few years complete structural coverage of the eight BET BRDs has also offered insight into their similarities and plasticity [1, 8-11] (**Figure 1E**) which has facilitated the design of inhibitors as we will later discuss.

Interactions initiated by BET proteins

The modular architecture of BET proteins is responsible for key interactions that facilitate the assembly of the transcriptional machinery. These include interactions initiated by the BRD modules and the ET domain (found in all four BET proteins) as well as the CTM motif found in BRD4 and BRDT.

Interactions with acetylated histones initiated by the bromodomain modules

BET bromodomains recognize and bind to acetylated lysine sequences found on histones or other proteins, an interaction initiated by a conserved asparagine residue found at the beginning of the BC-loop. A high resolution crystal structure of a histone H4 peptide acetylated at lysine 12 (H4K12ac) bound to the first bromodomain of BRD2 showed the acetylated lysine inserted deep into the Kac recognition cavity and coordinated to the conserved asparagine (N156) (**Figure 2A**). The protein:peptide interaction is driven mainly by the high electrostatic character of the surface surrounding the hydrophobic pocket where the neutralized Kac inserts (**Figure 2B**) [10]. In addition to binding single acetylated lysines, BET BRDs were recently found to bind to histone sequences bearing two acetylated lysines. This was first described in the case of the murine BRDT, which was crystallized with the diacetylated histone H4 peptide H4K5acK8ac [9]. The

diacetyl interaction was later found to be conserved and shared between the eight BET BRDs, for which both Kacs insert in the bromodomain cavity but only the N-terminal one initiates contacts with the conserved asparagine. The second Kac participates in a network of water-mediated interactions that further stabilize the first Kac within the cavity (**Figure 2C**). This mode of binding is conserved for other combinations of two acetylated lysines in histone H4, as seen in the crystal structure complexes of the first bromodomain of BRD4 with different H4 Kac mark combinations (**Figure 2D**) [1]. Interestingly, modified histone H3 peptides bearing propionylated or butyrylated lysines are also recognized by and bind to BET BRDs [12], suggesting that other lysine modifications may play a role in signalling, however this remains to be determined.

Interactions with other acetylated proteins initiated by the bromodomain modules

Beyond histones, BET BRDs have been recently found to bind to diverse acetylated proteins, including the RelA subunit of NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells), the transcription factors GATA1 and TWIST as well as cyclin-T1, a component of the positive transcription elongation factor b (P-TEFb). RelA is acetylated at lysine K310 by the histone acetyl transferase (HAT) CBP/p300, which trans-activates NF- κ B without affecting RelA binding to DNA or its association with the inhibitory protein I κ B α . RelA acetylated at K310 can be recognized by the BRDs of BRD4, resulting in the recruitment of the BRD4/NF- κ B complex to the promoter region of NF- κ B responsive genes, such as E-selectin and the pro-inflammatory cytokine TNF- α , stimulating their transcription [13].

Two acetylated lysines in close proximity, found on non-histone proteins, can also be recognized by BET BRDs in a similar mode to that observed for histones, as demonstrated for the erythroid and megakaryocyte-specific transcription factor GATA1. When acetylated, two conserved lysines on the C-terminal tail of GATA1 (K312 and K315) are recognized by the first BRD of BRD3 in a similar fashion to the interaction between BET BRDs and di-acetylated histone H4 peptides, albeit the GATA1 lysines bear different flanking residues [14]. This interaction, which seems to be initiated only by the first BRD of BRD3, is essential for erythropoiesis, as it results in stabilization of acetylated GATA1 bound onto chromatin, thus affecting the expression of GATA1-controlled genes [15]. A similar interaction was described recently in the case of the

epithelial-mesenchymal transition (EMT) transcription factor TWIST, which is a transcriptional activator that induces mesodermal gene expression. TWIST was found to interact with BRD4 in cells, an interaction that is driven by acetylation at two conserved lysines (K73 and K76) found at a region with sequence similarity to histone H4. This interaction was further shown to be initiated exclusively by the second BRD of BRD4 and was necessary for the expression of WNT5A, a critical ligand of both canonical (controlling pluripotency) and noncanonical (regulating motility and planar cell polarity) Wnt pathways. Thus, interaction between BRD4 and TWIST facilitates invasion, cancer stem cell-like properties and tumorigenicity in basal-like breast cancer cells [16] (although the exact roles of WNT5A are debated [17]).

Interactions involving acetylated cyclin-T1 (a component of P-TEFb) and the second BRD of BRD4 have also been shown to be necessary to stabilize the P-TEFb/BRD4 complex, resulting in activation of P-TEFb-responsive genes. Interestingly, *in vitro* experiments suggested that cyclin-T1 should carry three acetylated lysines in order to be sufficiently recognized by the second bromodomain of BRD4 (K380, K386 and K390) [18].

Interactions initiated by the extra-terminal domain

The extra-terminal domain of BET proteins is a protein:protein interaction motif that initiates interactions with viral proteins such as the latent nuclear antigen (LANA) of Kaposi's sarcoma-associated herpes virus [19], an interaction that was recently structurally characterized by NMR [20]. Importantly, recent evidence suggests that this domain can initiate protein:protein interactions with transcriptional effectors such as the methyltransferase NSD3, resulting in stimulation of transcription in a P-TEFb-independent manner [6]. This is the case of the short variant of BRD4, which lacks the CTM necessary for P-TEFb interactions (see next section). It remains to be seen if P-TEFb-independent stimulation of transcription, driven by the ET domain, is a feature shared between all BET proteins.

Interactions initiated by the C-terminal motif

The CTM of BRD4 interacts with the human papillomavirus (HPV) E2 protein, resulting in tethering of viral genomes to host mitotic chromosomes supporting low-level replication maintenance of the viral genome [7, 21] and transcriptional stimulation [22] as well as

transcriptional repression of the E6 and E7 viral oncoproteins that antagonize p53 and pRB tumor suppressor activity [23]. This interaction was recently found to be regulated by phosphorylation at S243 of the E2 protein [24]. The CTM also interacts with the P-TEFb complex, resulting in the dissociation of the inhibitory protein HEXIM1, thus enabling the active form of P-TEFb [18]. Recent data suggest that a region consisting of two basic clusters and a hydrophobic stretch on the CTM of BRD4 is able to stimulate the kinase activity of CDK9 above basal levels, even in the presence of the inhibitory protein HEXIM1, however the precise mechanism of CDK9 stimulation is still not well understood [25]. Interestingly, the HPV E2 interaction with BRD4 is necessary for the recruitment of P-TEFb to the HPV early promoter [26], however there is also evidence that E2 binding competitively inhibits the BRD4/P-TEFb complex [27]. The precise contribution of BRD4 to the mechanism(s) of E2-controlled transcriptional stimulation therefore remains unknown.

The modular architecture of BET proteins facilitates multi-point interactions resulting in the assembly of complexes tethered to chromatin. BET complexes with diverse protein partners resulting through interactions initiated by the ET domain and CTM are tethered to acetylated chromatin via the BRD modules. At the same time the BRD modules may act to stabilize secondary interactions with the same or other acetylated protein partners. Ultimately these large assemblies affect transcriptional programmes and can be tightly controlled. It will be interesting to see how the specific readout of two acetylated lysines correlates with the transcriptional attenuation conferred by BETs. A common theme in the assembly of such complexes is the recognition of acetyl lysine by the BRD modules, an event that can be targeted by small molecule inhibitors (Box 1). Next we will discuss how BETs participate in transcription in the context of these protein assemblies.

BET role(s) in transcription

BET proteins play a central role in chromatin biology by acting as tissue-specific recruitment platforms that tether complexes to acetylated histones and chromatin. BRD2 for example plays a key role in neuronal development, controlling neuronal differentiation, cell cycle progression, and

cell cycle exit in neuroepithelial cells [35]. For example, in mitogen-stimulated primary B cells BRD2 controls cyclin A expression by directly binding to the cyclin A promoter, affecting S-phase progression [36]. In HeLa cells BRD2 has yet another function; it was found to affect alternative splicing of multiple genes without affecting RNA polymerase II processivity downstream of the alternatively spliced elements. The affected genes included some involved in MAPK signalling and the response to growth factor stimuli [37].

BRD3 plays a role in erythropoiesis by directly interacting with the transcription factor GATA1, which induces all known erythroid-specific genes while repressing genes associated with the proliferative, immature state. The complex of BRD3 with GATA1 stabilizes the association of the transcription factor with chromatin, affecting the transcription of its responsive genes [14, 15]. Although BRD3 binds to the majority of GATA1 regulated genes, its displacement from chromatin by employing the BET inhibitor (+)-JQ1 (see Box 1) affected only GATA1-mediated transcriptional activation, and not transcriptional repression on a genome-wide scale [38]. More importantly, BRD2 and BRD4 were also found to bind to a subset of GATA1-related genes and their depletion blunted erythroid gene activation. Depletion of BRD3 only affected erythroid transcription if BRD2 was also deficient [38], suggesting that BET proteins may have overlapping roles that need to be further investigated.

BRD4 and more recently BRDT have been established as central regulators of transcriptional elongation by recruiting the P-TEFb complex to chromatin [39-41]. BRD4 (and most likely BRDT) facilitate the dissociation of the inhibitory factors HEXIM1 resulting in an active form of P-TEFb, which in turn phosphorylates and activates RNA-Pol-II [18]. The recent use of BET inhibitors helped establish that BETs mainly control lineage specific genes. For instance, when BRD4 is displaced from chromatin in CD4⁺ T-cells, RNA Pol II phosphorylation is affected resulting in down-regulation of genes that are largely T-cell specific [42]. Transcriptional attenuation through P-TEFb is also achieved by physical interaction of BRD4 with the JmjC-domain containing protein JMJD6. This allows for H4R3me_{2(sym)} and 7SK snRNA demethylation, thus releasing the 7SK snRNA/HEXIM1 inhibitory complex imposed on the P-TEFb complex and leading to promoter-proximal Pol II pause release and transcriptional reactivation, while maintaining

association of the P-TEFb complex with chromatin [43]. Additional evidence suggests that BRD4 occupies widespread genomic regions to stimulate directly elongation of both protein-coding transcripts and noncoding enhancer RNAs, assisting Pol II in progression through hyperacetylated nucleosomes while facilitating interactions with acetylated histones via its BRD modules [44]. Many M/G1 genes that are programmed to be expressed at the end of mitosis have been known to be bound by BRD4 [45] and additional evidence recently suggested a role for this protein in gene bookmarking: facilitating post-mitotic transcriptional reactivation by accelerating the kinetics of transcription and helping to decompact chromatin in daughter cells [46]. Further evidence supports a model whereby BRD4 interactions with chromatin help maintain chromatin structure and morphology [47]. Interestingly, a short variant of BRD4 lacking the C-terminal motif responsible for P-TEFb interaction functions as an endogenous inhibitor of DNA damage response signalling by recruiting the condensin II chromatin remodelling complex to acetylated histones. This stimulated chromatin reorganization and compaction, while depletion of this variant resulted in rapid cell-cycle checkpoint recovery and enhanced cell survival [48]. A similar effect was previously reported for a C-terminal truncation of the testis specific BET isoform (BRDT) which also stimulated chromatin compaction [49] suggesting that a regulatory role in chromatin de-compaction may be attributed to the CTM found on the longer BET variants (BRD4 and BRDT).

BRDT has a central role in chromatin remodelling during spermatogenesis as indicated by the importance of its first bromodomain in maintaining chromatin architecture of the sperm head [50]. A recent study delineated BRDT's role in re-organizing chromatin, facilitating histone eviction and replacement by transition proteins, establishing it as an essential factor for male germ cell differentiation [41]. BRDT was further shown to regulate meiotic divisions and post-meiotic genome repackaging, functions that were found to be dependent on its first bromodomain [41]. BRDT has also been suggested as a target for male contraception [11].

The modular interactions initiated by the extra-terminal domain, which is conserved in BETs, can also stimulate transcription in a P-TEFb-independent manner by affecting the chromatin micro-environment of BET target genes. This was demonstrated for BRD4-recruited NSD3, a

methyltransferase that was shown to regulate the levels of histone H3 K36 methylation, which is a modification that is enriched in regions of active transcription [6]. It remains to be seen if all BETs can adopt similar P-TEFb-independent roles in transcription.

BET proteins are key tissue-specific chromatin adaptors and recruitment platforms that help attenuate diverse transcriptional programs, from neuronal development to erythropoiesis and spermatogenesis as well as alternative splicing. Many of these functions seem to be overlapping, such as control of erythropoiesis, while others seem to be very specific, such as spermatogenesis, suggesting that complicated and non-overlapping mechanisms of regulation are in place. It is therefore not surprising that BET functions are found to be perturbed in disease, including cancer, inflammation and viral infection. We will next discuss how these proteins are deregulated in such disease settings.

BET proteins in disease

As key drivers of transcription BET proteins are often deregulated in disease, affecting a number of growth promoting genes and cytokines.

BET role(s) in cancer

BET proteins have been known to be deregulated in cancer [51] and the availability of potent inhibitors (see Box 1) in the last five years has helped to better understand the specifics behind diverse tumor types. For example a role for BRD2 has recently been investigated in lung induced adenocarcinoma. In this system, BRD2 was found to form a complex with RUNX3 in a K-RAS-dependent fashion. This complex induced the expression of the cell-cycle inhibitor p21, thus the study provided insight into K-Ras-driven oncogenic functions [52]. Oncogenic fusions involving BET proteins have also been identified, leading to tumorigenic functions. BRD3 and BRD4 have been involved in chromosomal translocations leading to tumorigenic fusions with the nuclear protein in testis (NUT) leading to NUT midline carcinomas (NMCs), which are rare and aggressive carcinomas that have no organ or tissue of origin [53]. The *BRD4* locus (19p13.1) (or *BRD3* locus, 9q34.2) and *NUT* locus (15q14) translocate to create a *BRD4–NUT* fusion gene whose product is driven by the *BRD4* promoter. The *BRD4–NUT* fusion product blocks

differentiation and maintains tumour growth, although the mechanism is not clear. Early studies established that the fusion product induces formation of hyper-acetylated, transcriptionally inactive foci by direct recruitment of the acetyltransferase p300, resulting in local hyper-acetylation, as well as acetylation and therefore deactivation of p53 [54]. Dispersion of these foci by various methods, including incapacitating the ability of BRD4 to bind to acetylated chromatin via its bromodomain, was sufficient to restore cellular functions. Interestingly, global acetylation was shown to be decreased, which should result in down-regulation of many genes [55], however hyper-acetylation of chromatin results in subsequent recruitment of BRD4 and further transcriptional stimulation [56]. Although the precise mechanism of action is yet to be uncovered it is thought that the fusion product affects the transcription of pro-proliferative and anti-differentiation genes, such as *MYC*, which is supported by recent evidence that the fusion protein is present at the *MYC* promoter, maintaining *MYC* expression [57]. Observation that genetic knockdown of the BRD4-NUT product results in squamous differentiation and G1 cell cycle arrest, and that this effect is phenocopied by the pan-BET inhibitor (+)-JQ1 in mouse xenograft models of NMC [29], has led to several clinical trials employing thieno- and benzo-diazepines in the past few years (Table 1).

Pan-BET inhibitors down-regulate *MYC* expression in many diverse tumour settings. This was first described in myeloma [58, 59] and later in Burkitt's lymphoma [60], and has now also been described for acute myeloid and mixed lineage leukemia [61-65], acute lymphoblastic leukaemia (ALL) and T-cell ALL [66-69], medulloblastoma [70-72], glioblastoma [73], prostate cancer [74-76], lung adenocarcinomas [77], lung cancer and non-small cell lung cancer [78], ovarian cancer [79, 80], skin cancers [81, 82], as well as in Estrogen Receptor-positive breast cancers [83]. The c-MYC isoform N-MYC was also found to be down-regulated in neuroblastoma by BET inhibitors [84-86] and generation of Cre-conditional human MYCN-driven mouse models that closely recapitulate the human disease with respect to tumor localization, histology, marker expression and genomic makeup have been reported [87]. However, recent studies have identified diverse tumours where *MYC* is not down-regulated following BET inhibition, suggesting that *MYC* expression is driven by unique, tumour-type specific, regulatory mechanisms [88, 89].

The collective findings of many studies employing pan-BET inhibitors suggests that down-regulation of anti-apoptotic and growth-promoting genes is highly selective, while the effect of BET inhibition is context-dependent, suggesting that displacement of BETs from gene promoters is only in part responsible for the observed changes in transcription upon BET inhibition. Recent chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) data suggests that both BRD4 and the Mediator complex are co-occupying large numbers of enhancer regions as well as a small set of exceptionally large super-enhancers [90] that seem to be responsible for the increased expression of key transcription factors in cancer, such as the MYC oncogene [91] (**Figure 3A**). Intriguingly, BET inhibition seems to preferentially displace BRD4 from these super-enhancers, offering a potential strategy for selective targeting of certain oncogenes [92].

BET role(s) in inflammation

BET proteins play a central role in inflammatory responses by directly facilitating the transcriptional activation of pro-inflammatory cytokines. This occurs mainly through interactions with NF- κ B and by direct recruitment of P-TEFb to NF- κ B-dependent acetylated histones, resulting in stimulation of primary response genes [2, 51]. Inhibition of BETs using pan-BET inhibitors also strongly affects the expression of many secondary response pro-inflammatory genes. Typically these are induced during the late stage of macrophage activation in response to lipopolysaccharide (LPS) stimulation and BET inhibition results in protection from LPS-induced endotoxic shock and bacteria-induced sepsis in mice [30]. Interestingly, inhibition of BRD4 also resulted in ubiquitylation and degradation of the constitutively active nuclear form of RelA [93]. NF- κ B has been shown to rapidly migrate to *de novo* enhancers post LPS treatment [94] suggesting a potential mechanism for the sequestration of BRD4 in super-enhancer-enriched regions, offering an explanation for the attenuation conferred on NF- κ B controlled genes by pan-BET inhibitors [95]. Additionally, enhancer RNAs (eRNA) were shown to be dynamically induced at most of the innate immunity and inflammation driver genes, which are also associated with super-enhancer domains, following toll-like receptor stimulation. The dynamic induction of eRNAs was shown to further attenuate gene transcription in a BRD4-dependent manner [96] (**Figure 3B**).

An intriguing link has also been established between BET proteins and *in vitro* cardiomyocyte hypertrophy and *in vivo* pathologic cardiac remodelling [97]. The authors found that BRD4 is at least in part responsible for the expression of transcription factors that control pathological gene expression during heart remodelling and heart failure, such as GATA4 and NFAT. Direct BRD4 inhibition in murine models abolished many characteristics of pathological remodelling, including an increase in cardiomyocyte volume and activation of inflammatory pathways, offering a potential therapeutic target for heart-failure pathogenesis.

BET role(s) in viral infection

Interactions of viral oncoproteins with BET proteins have been examined in the past, establishing a role for BETs in tethering viral genomes to mitotic chromosomes. This function of BETs contributes to the segregation of human papilloma virus (HPV), Epstein Barr Virus (EBV), Kaposi's sarcoma-associated Herpes virus (KSHV), Merkel cell polyoma virus (MCV) and murine leukemia virus (MLV) genomes [2]. For instance, BRD4 co-localizes with the viral E1 and E2 proteins at early stages of HPV infection, facilitating viral genome tethering to the host genome and generation of foci that recruit additional factors. However, BRD4 is displaced from these foci during viral replication, suggesting that it plays a role in sequestering factors essential for viral replication at early stages but is not essential for viral DNA amplification [98]. In addition, BET interactions with viral proteins are at least in part responsible for the stabilization of the viral partners within the nucleus, by preventing them from cytosolic ubiquitylation and proteasomal degradation [99]. Analysis of CHIP-seq data also demonstrated interplay between EBV nuclear antigens (EBVNAs, viral oncoproteins responsible for growth and survival) and NF- κ B subunits, which were found to co-occupy sites with high H3K27ac density (a hallmark of super-enhancers). These so called EBV super-enhancer sites were shown to regulate key B-cell growth and survival genes such as *MYC* and *BCL2* and were sensitive to BET inhibition [100] (**Figure 3C**). It remains to be seen if BET participation in super-enhancer function is a generic mechanism of viral infection.

Direct inhibition of BETs was also shown to reactivate latent HIV, although the precise mechanism differs between BET proteins. While BRD2 associates with E2F1 and NF- κ B at the

HIV promoter, repressing *HIV* transcription [101], BRD4 blocks the interaction of the *HIV* transactivator Tat protein with the super elongation complex at the *HIV* promoter [102]. Release of the BET proteins using pan-BET inhibitors resulted in latent reactivation of the virus and stimulated *HIV* replication, offering a potential therapeutic strategy for eliminating latent *HIV* [103].

Clinical validation of BETs

The disclosure of highly potent and selective BET inhibitors, and the remarkable follow-up and use of these tool compounds, have generated a wealth of information on BET function in multiple survival pathways. Several studies have already combined current treatment with BET inhibitors demonstrating synergy and improved therapeutic potential [69, 83, 104-108]. At the same time many translational projects have been stimulated resulting in several clinical trials seeking to modulate BETs in diverse settings, particularly in oncology. Currently, several trials are in progress seeking to attenuate BETs in leukemias, lymphomas, myelomas, glioblastomas, non-small cell lung cancer, and NUT midline carcinomas (**Table 1**). Although the BET inhibitors were discovered through a phenotypic screen for regulation of the expression of the APO-A1 protein, which is responsible for reverse cholesterol transport, the transcriptional attenuation of this gene by BETs is unclear [65]. The link between BETs and conditions such as diabetes and atherosclerosis is not entirely understood; two clinical trials that sought to target BETs in this context (**Table 1**) have been completed, however the precise outcome has not been disclosed and remains to be determined.

Concluding remarks

BET proteins are key players in transcription, controlling gene expression in inflammation, viral infection and cancer biology. The recent disclosure of pan-BET inhibitors that attenuate bromodomain function has allowed for wide validation of these drug targets, shedding light on their role(s) in disease. Diverse transcriptional programmes are attenuated in a tissue-specific manner by BETs, and pre-clinical targeting of BETs has had initial success, justifying the need for selective tools to better modulate their function. It will be challenging to target specific diseases without severe side effects, given the diverse and tissue-specific roles of individual

BRDs. For instance, BRD2 is involved in differentiation in neurons and adipose tissue [35, 109], but also haematopoiesis [38] and juvenile myoclonic epilepsy [110, 111]; BRD3 is involved in erythropoiesis [14, 15]; BRD4 is involved in transcriptional activation [39], noncoding enhancer RNAs elongation [44], chromatin structure and morphology [47] as well as DNA-damage response [48]; and BRDT is involved in spermatogenesis [11, 41]. Despite the encouraging phase I responses [112], concerns have been raised on the safety of pan-BET inhibition. When targeting BETs, care must be taken to monitor the effects on super-enhancer-controlled stem cell-specific transcription factors, such as OCT4 and PRDM14, which control stem cell identity and cell fate decisions [113]. Indeed, direct inhibition of BRD4 in mice was recently shown to stimulate epidermal hyperplasia, alopecia, decreased cellular diversity and stem cell depletion in the small intestine as well as sensitivity to organ stress [114]. In addition, BET inhibition resulted in strong modulation of the innate immune response, increasing the risk of infections when used clinically. For example, (+)-JQ1 treatment of mice infected with the bacterial pathogen *Listeria monocytogenes* reduced NO production and increased the animal's susceptibility to develop colitis due to strong down-regulation of Nitric oxide synthase 2 expression [115]. Lastly, Brd2-hypomorphic mice are severely obese [116], suggesting potential metabolic effects of BET inhibition. However, no *in vivo* data or clinical studies have demonstrated that targeting BRD2 may result in weight gain, although this must be further examined. These examples highlight the urgent need for novel selective tools that will improve understanding of the biology of each BET protein, in order to develop safe and effective novel drugs.

Acknowledgements

We apologize to all authors whose important contributions could not be acknowledged due to space limitations. The authors are grateful for support for their research received from the SGC, a registered charity (number 1097737) that receives funds from the Canadian Institutes for Health Research, the Canada Foundation for Innovation, Genome Canada, GlaxoSmithKline, Pfizer, Eli Lilly, Takeda, AbbVie, the Novartis Research Foundation, Bayer, the Ontario Ministry of Research and Innovation and the Wellcome Trust (Grant # 092809/Z/10/Z). C-Y.W. and P.F. are supported by a Wellcome Trust Career-Development Fellowship (Grant # 095751/Z/11/Z).

Box 1. Inhibition of BET bromodomain:peptide interactions

The hydrophobic nature of the acetyl-lysine cavity allowed for the development of small molecule compounds that disrupt BRD/Kac interactions. Following disclosure of a triazolo-thienodiazepine scaffold in the patent literature in 2009 [28] two key compounds were characterized, the triazolo-thienodiazepine (+)-JQ1 [29] and the triazolo-benzodiazepine I-BET762 [30]. These highly potent and selective inhibitors target only BET BRDs and are capable of dissociating BET proteins from chromatin, affecting the transcriptional programs that they control. Since 2010 several potent and selective compounds have been developed (recently reviewed elsewhere [2]) and widely distributed allowing for thorough validation of BET function in chromatin biology and disease. Some of the most advanced BET BRD inhibitors (in terms of potency and selectivity against other BRDs) are summarized in **Figure I**. Interestingly, certain advanced kinase inhibitors that were thought to be highly selective have been found to target BET BRDs [31-34]. Of particular interest are the JAK2/FLT3 kinase inhibitor fedratinib and the PLK1 inhibitor BI-2536, which exhibited low nanomolar affinity for the first BRD of BRD4. These inhibitors were used in cellular assays to target BRD4 at clinically relevant concentrations, leading to potential applications in developing poly-pharmacology aiming to attenuate both BET and kinase phenotypes in diverse diseases [31]. Kinase inhibitors that have been shown to be highly potent towards BET BRDs are also shown in **Figure I** (lower panel). The plasticity and features of the bromodomain modules of BETs are well established so it remains to be seen if specific and selective inhibitors will emerge for each of the four proteins, or for individual domains within proteins. Such selective compounds would help delineate the role(s) of each BET protein in biology.

Figures

Figure 1




Figure 1 - Domain organization of BET proteins and module structures. (A) Bromo and extra-terminal proteins contain a modular architecture, including two N-terminal tandem bromodomain modules (BD1, BD2 shown in blue) responsible for acetyl-lysine recognition and an extra-terminal protein-protein interaction domain (ET, shown in orange). BRDT as well as the long variant of BRD4 (BRD4L), contain a C-terminal motif (CTM, shown in dark blue), which interacts with the positive transcription elongation factor b (P-TEFb). The CTM is sometimes

referred to as P-TEFb interacting domain (PID). Several conserved motifs are also present (A, B motifs shown in green and dark red respectively) as well as a serine-glutamate-aspartate rich region (SEED). Domain boundaries for all family members are annotated in figure. **(B)** Crystal structure of the human BRD2 first bromodomain module (BD1 or BRD2(1); from PDB ID: 2DVQ) [10]. Structural elements are annotated in the figure and the conserved asparagine is shown in stick representation. **(C)** Solution structure of the murine BRD4 ET domain (from PDB ID: 2JNS) [5]. Structural elements are annotated in the figure. **(D)** Crystal structure of human papillomavirus protein E2 in complex with a CTM-peptide of BRD4 (residues 1343-1362) showing binding of the BRD4-CTM on a basic groove of the E2 protein [7]. The electrostatic potential of the viral protein is coloured as indicated in the inset. **(E)** Electrostatic potential of BET BRDs calculated from high resolution crystal structures of the human (or murine in the case of BRD2(2)) modules [1, 8-11]. The structures are oriented with the acetyl-lysine binding cavity facing outwards, annotated with a dotted circle and the electrostatic potentials are coloured as indicated in the inset. PDB IDs (<http://www.pdb.org>) are given for each protein module.

Figure 2




Figure 2 - Mode of histone sequence recognition by BET bromodomains. BET bromodomains can recognize and bind to single as well as double acetyl-lysine marks. **(A)** Crystal structure of the first bromodomain of human BRD2 in complex with a histone H4 peptide acetylated at K12 (PDB ID: 2DVQ) [10]. The acetylated lysine engages the protein directly via the conserved asparagine (N156 in BRD2 BD1) and fits within the cavity formed by several conserved residues highlighted and annotated on the structure. **(B)** Complex of BRD2 BD1 with the histone peptide shown in (A), with the protein surface coloured according to the electrostatic potential of the residues found on the module's surface (as indicated on the inset), highlighting the charged nature of the area surrounding the central hydrophobic acetyl-lysine recognition site. The acetylated lysine and the peptide termini have been annotated in the inset. **(C)** Crystal structure of the first bromodomain of human BRD4 in complex with a histone H4 di-acetylated peptide (at K5 and K8, PDB ID: 3UVW) [1]. While the first acetyl-lysine (K5ac) directly engages

the protein via the conserved asparagine residue (N140 in BRD4 BD1) (and is further stabilized via a water mediated interaction to Y97), the second acetyl-lysine (K8ac) stabilizes the peptide fold via water-mediated bridges to K5ac and to BRD4 Q85. **(D)** Surface representation of the electrostatic potential of human BRD4 BD1 (from PDB ID: 3UVW) in complex with a histone H4 peptide (H4K5acK8ac from PDB ID: 3UVW) superimposed to other double-acetylated peptide complexes of BRD4 BD1 (H4K12acK16ac from PDB ID: 3UVX and H4K16acK20ac from PDB ID: 3UVY). The surface is coloured as indicated on the inset. All three complexes retain the mode of interactions seen in (C) with both acetylated lysines filling the entire recognition cavity.

Figure 3





Figure 3 - Transcriptional attenuation by BRD4. (A) BRD4 has been found to be particularly enriched at enhancer and super-enhancer regions strongly stimulating the expression of oncogenes in cancer. BRD4 is able to recruit the mediator complex to acetylated chromatin sites via its bromodomain modules, effectively stimulating transcription. In a cascade of events, the serine/threonine protein kinase PIM1 phosphorylates histone H3 at serine 10, an event that helps recruit a 14-3-3 protein that in turn recruits the acetyl-transferase MOF, resulting in

acetylation of histone H4, thus generating new docking sites for BRD4. BRD4 also recruits (via its C-terminal motif and bromodomain) the positive transcription elongation factor b (P-TEFb, the complex of CDK9 and cyclin-T1) to promoter regions, leading to phosphorylation of the carboxy-terminal repeats of RNA polymerase II, which re-activates the paused polymerase complex stimulating elongation [117]. Image adapted from reference [2]. **(B)** Inflammatory stimuli can result in redistribution of chromatin activators to *de novo* massive clustered enhancer domains (super enhancers). An inflammatory stimulus (such as tumour necrosis alpha) can cause sequestration of NF-κB and other co-factors (including BRD4) from the basal Super Enhancer, redistributing these factors to a new Super Enhancer that stimulates the transcription of pro-inflammatory genes. Image adapted from reference [95]. **(C)** EBV infection drives formation of Super Enhancers that drive transcription. Upon infection, viral oncoproteins are expressed and activate NF-κB resulting in viral and NF-κB subunits occupying primed B cell enhancer sites, recruiting additional cell transcription factors (including adaptor proteins such as BRD4) and nucleating EBV Super-Enhancers effectively up-regulating transcription of growth promoting genes (*MYC*, *BCL2* etc). EBV: Epstein Barr Virus; TF: transcription factor. Image adapted from reference [100].

Box 1 – Figure 1



Box 1, Figure 1 - Advanced BET inhibitors. Several chemical series have been developed targeting BET bromodomains, with triazolo-thieno- and triazolo-benzo-diazepines currently in clinical testing. The most potent and advanced pan-BET inhibitors employing diverse chemical templates are shown here. The equivalent name from each patent (where applicable) as well as the chemical class are also given. Diverse kinase inhibitors were also shown to exhibit very high affinity towards BET bromodomains and the most potent of these compounds are shown on the bottom panel, annotated with their primary kinase target(s). In all cases, the acetyl-lysine mimetic part of a molecule is highlighted in red.

Tables

Table 1 – Bromodomain Inhibitors in clinical development

Company	Compound	Trial*	Phase	Start Date	Indications
Bayer	BAY1238097 (not disclosed)	NCT02369029	I	02/2015	Neoplasms
Constellation	CPI-0610 (triazolo- benzo- diazepine class)	NCT01949883	I	09/2013	Lymphoma
		NCT02158858	I	06/2014	Acute Leukemia (AML) Myelodysplastic Syndrome (MDS) Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
		NCT02157636	I	07/2014	Multiple myeloma
GlaxoSmithKline	GSK525762 (triazolo- benzo- diazepine class)	NCT01587703	I	03/2012	Midline Carcinoma
		NCT01943851	I	05/2014	Cancer
OncoEthix	OXT015 (Triazolo- thieno- diazepine class in- license from Tanabe Mitsubishi)	NCT01713582	I/II	12/2012	Acute Leukemia Other Hematological Malignancies
		NCT02259114	I	11/2014	NUT Midline Carcinoma Triple Negative Breast Cancer Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Castrate-resistant Prostate Cancer (CRPC) Pancreatic Ductal Adenocarcinoma
		NCT02296476	I/II	11/2014	Glioblastoma Multiforme
	OXT015 & Vidaza (azacitidine)	NCT02303782	I/II	01/2015	Acute Myeloid Leukemia
Resverlogix	RVX000222 (quinazolinone class)	NCT01058018 <i>(completed)</i>	II	12/2009	Atherosclerosis Coronary Artery Disease
		NCT01728467 <i>(completed)</i>	II	11/2012	Diabetes
Tensha Therapeutics	TEN-010 (triazolo- thieno- diazepine class)	NCT01987362	I	10/2013	Solid Tumors
		NCT02308761	I	10/2014	Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

* Data taken from <http://www.clinicaltrials.org>

References

- 1 Filippakopoulos, P., *et al.* (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell* 149, 214-231
- 2 Filippakopoulos, P. and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat Rev Drug Discov* 13, 337-356
- 3 Fukazawa, H. and Masumi, A. (2012) The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal. *Biol Pharm Bull* 35, 2064-2068
- 4 Garcia-Gutierrez, P., *et al.* (2012) Association of bromodomain BET proteins with chromatin requires dimerization through the conserved motif B. *J Cell Sci* 125, 3671-3680
- 5 Lin, Y.J., *et al.* (2008) Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4. *Protein Sci* 17, 2174-2179
- 6 Rahman, S., *et al.* (2011) The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. *Mol Cell Biol* 31, 2641-2652
- 7 Abbate, E.A., *et al.* (2006) Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. *Mol Cell* 24, 877-889
- 8 Nakamura, Y., *et al.* (2007) Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4. *J Biol Chem* 282, 4193-4201
- 9 Moriniere, J., *et al.* (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. *Nature* 461, 664-668
- 10 Umehara, T., *et al.* (2010) Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. *J Biol Chem* 285, 7610-7618
- 11 Matzuk, M.M., *et al.* (2012) Small-molecule inhibition of BRDT for male contraception. *Cell* 150, 673-684
- 12 Vollmuth, F. and Geyer, M. (2010) Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. *Angew Chem Int Ed Engl* 49, 6768-6772
- 13 Huang, B., *et al.* (2009) Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. *Mol Cell Biol* 29, 1375-1387
- 14 Gamsjaeger, R., *et al.* (2011) Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. *Mol Cell Biol* 31, 2632-2640
- 15 Lamonica, J.M., *et al.* (2011) Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. *Proc Natl Acad Sci U S A* 108, E159-168
- 16 Shi, J., *et al.* (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. *Cancer Cell* 25, 210-225
- 17 Borcherdig, N., *et al.* (2015) Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells. *Cancer Res* 75, 1972-1982
- 18 Schroder, S., *et al.* (2012) Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. *J Biol Chem* 287, 1090-1099
- 19 You, J., *et al.* (2006) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. *J Virol* 80, 8909-8919

- 20 Hellert, J., *et al.* (2013) A structural basis for BRD2/4-mediated host chromatin interaction and oligomer assembly of Kaposi sarcoma-associated herpesvirus and murine gammaherpesvirus LANA proteins. *PLoS Pathog* 9, e1003640
- 21 You, J., *et al.* (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. *Cell* 117, 349-360
- 22 Smith, J.A., *et al.* (2010) Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. *Proc Natl Acad Sci U S A* 107, 3752-3757
- 23 Wu, S.Y., *et al.* (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. *Genes Dev* 20, 2383-2396
- 24 Chang, S.W., *et al.* (2014) Phosphorylation of HPV-16 E2 at serine 243 enables binding to Brd4 and mitotic chromosomes. *PLoS One* 9, e110882
- 25 Itzen, F., *et al.* (2014) Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. *Nucleic Acids Res* 42, 7577-7590
- 26 Helfer, C.M., *et al.* (2014) The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation. *Viruses* 6, 3228-3249
- 27 Yan, J., *et al.* (2010) Abrogation of the Brd4-positive transcription elongation factor B complex by papillomavirus E2 protein contributes to viral oncogene repression. *J Virol* 84, 76-87
- 28 Miyoshi, S., *et al.* Mitsubishi Tanabe Pharma Corporation, Japan. Antitumor agent, WO 2009/084693 A1
- 29 Filippakopoulos, P., *et al.* (2010) Selective inhibition of BET bromodomains. *Nature* 468, 1067-1073
- 30 Nicodeme, E., *et al.* (2010) Suppression of inflammation by a synthetic histone mimic. *Nature* 468, 1119-1123
- 31 Ciceri, P., *et al.* (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. *Nat Chem Biol* 10, 305-312
- 32 Martin, M.P., *et al.* (2013) Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. *ACS Chem Biol* 8, 2360-2365
- 33 Dittmann, A., *et al.* (2014) The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. *ACS Chem Biol* 9, 495-502
- 34 Ember, S.W., *et al.* (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. *ACS Chem Biol* 9, 1160-1171
- 35 Tsume, M., *et al.* (2012) Brd2 is required for cell cycle exit and neuronal differentiation through the E2F1 pathway in mouse neuroepithelial cells. *Biochem Biophys Res Commun* 425, 762-768
- 36 Belkina, A.C., *et al.* (2014) The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. *J Leukoc Biol* 95, 451-460
- 37 Hnilicova, J., *et al.* (2013) The C-terminal domain of Brd2 is important for chromatin interaction and regulation of transcription and alternative splicing. *Mol Biol Cell* 24, 3557-3568
- 38 Stonestrom, A.J., *et al.* (2015) Functions of BET proteins in erythroid gene expression. *Blood* 125, 2825-2834
- 39 Jang, M.K., *et al.* (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. *Mol Cell* 19, 523-534
- 40 Yang, Z., *et al.* (2005) Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. *Mol Cell* 19, 535-545

- 41 Gaucher, J., *et al.* (2012) Bromodomain-dependent stage-specific male genome programming by Brdt. *EMBO J* 31, 3809-3820
- 42 Zhang, W., *et al.* (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4⁺ T cells. *J Biol Chem* 287, 43137-43155
- 43 Liu, W., *et al.* (2013) Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. *Cell* 155, 1581-1595
- 44 Kanno, T., *et al.* (2014) BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. *Nat Struct Mol Biol* 21, 1047-1057
- 45 Dey, A., *et al.* (2009) Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. *Mol Biol Cell* 20, 4899-4909
- 46 Zhao, R., *et al.* (2011) Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. *Nat Cell Biol* 13, 1295-1304
- 47 Wang, R., *et al.* (2012) Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. *J Biol Chem* 287, 10738-10752
- 48 Floyd, S.R., *et al.* (2013) The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. *Nature* 498, 246-250
- 49 Pivot-Pajot, C., *et al.* (2003) Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. *Mol Cell Biol* 23, 5354-5365
- 50 Berkovits, B.D. and Wolgemuth, D.J. (2011) The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background. *Dev Biol* 360, 358-368
- 51 Belkina, A.C. and Denis, G.V. (2012) BET domain co-regulators in obesity, inflammation and cancer. *Nat Rev Cancer* 12, 465-477
- 52 Lee, Y.S., *et al.* (2013) Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. *Cancer Cell* 24, 603-616
- 53 French, C. (2014) NUT midline carcinoma. *Nat Rev Cancer* 14, 149-150
- 54 Reynoird, N., *et al.* (2010) Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. *EMBO J* 29, 2943-2952
- 55 Schwartz, B.E., *et al.* (2011) Differentiation of NUT midline carcinoma by epigenomic reprogramming. *Cancer Res* 71, 2686-2696
- 56 Wang, R. and You, J. (2015) Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation. *J Biol Chem* 290, 2744-2758
- 57 Grayson, A.R., *et al.* (2014) MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. *Oncogene* 33, 1736-1742
- 58 Delmore, J.E., *et al.* (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* 146, 904-917
- 59 Chaidos, A., *et al.* (2014) Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. *Blood* 123, 697-705
- 60 Mertz, J.A., *et al.* (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci U S A* 108, 16669-16674
- 61 Dawson, M.A., *et al.* (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. *Nature* 478, 529-533

- 62 Zuber, J., *et al.* (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature* 478, 524-528
- 63 Herrmann, H., *et al.* (2012) Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. *Oncotarget* 3, 1588-1599
- 64 Fiskus, W., *et al.* (2014) Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. *Mol Cancer Ther* 13, 1142-1154
- 65 Picaud, S., *et al.* (2013) PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. *Cancer Res* 73, 3336-3346
- 66 Ott, C.J., *et al.* (2012) BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. *Blood* 120, 2843-2852
- 67 Da Costa, D., *et al.* (2013) BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. *Blood Cancer J* 3, e126
- 68 Roderick, J.E., *et al.* (2014) c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. *Blood* 123, 1040-1050
- 69 Tan, Y., *et al.* (2015) Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. *Cancer Biol Ther* 16, 580-588
- 70 Henssen, A., *et al.* (2013) BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. *Oncotarget* 4, 2080-2095
- 71 Bandopadhyay, P., *et al.* (2014) BET bromodomain inhibition of MYC-amplified medulloblastoma. *Clin Cancer Res* 20, 912-925
- 72 Venkataraman, S., *et al.* (2014) Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. *Oncotarget* 5, 2355-2371
- 73 Rajagopalan, V., *et al.* (2014) Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. *Cell Mol Neurobiol* 34, 1059-1069
- 74 Gao, L., *et al.* (2013) Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. *PLoS One* 8, e63563
- 75 Asangani, I.A., *et al.* (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. *Nature* 510, 278-282
- 76 Cho, H., *et al.* (2014) RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. *Cancer Discov* 4, 318-333
- 77 Tsai, L.H., *et al.* (2015) The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. *Oncogene* 34, 1641-1649
- 78 Shimamura, T., *et al.* (2013) Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. *Clin Cancer Res* 19, 6183-6192
- 79 Baratta, M.G., *et al.* (2015) An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. *Proc Natl Acad Sci U S A* 112, 232-237
- 80 Qiu, H., *et al.* (2015) JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. *Oncotarget* 6, 6915-6930
- 81 Segura, M.F., *et al.* (2013) BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. *Cancer Res* 73, 6264-6276
- 82 Shao, Q., *et al.* (2014) BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. *Cancer Res* 74, 7090-7102

- 83 Bihani, T., *et al.* (2015) Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. *Oncotarget* 6, 2407-2420
- 84 Puissant, A., *et al.* (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. *Cancer Discov* 3, 308-323
- 85 Wyce, A., *et al.* (2013) BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. *PLoS One* 8, e72967
- 86 Shahbazi, J., *et al.* (2014) Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. *Oncotarget* 5, 4257-4268
- 87 Althoff, K., *et al.* (2014) A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. *Oncogene* doi:10.1038/onc.2014.269
- 88 Fowler, T., *et al.* (2014) Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. *PLoS One* 9, e87003
- 89 Kumar, K., *et al.* (2015) GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. *Sci Rep* 5, 9489
- 90 Hnisz, D., *et al.* (2013) Super-enhancers in the control of cell identity and disease. *Cell* 155, 934-947
- 91 Mansour, M.R., *et al.* (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. *Science* 346, 1373-1377
- 92 Loven, J., *et al.* (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* 153, 320-334
- 93 Zou, Z., *et al.* (2014) Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. *Oncogene* 33, 2395-2404
- 94 Kaikkonen, M.U., *et al.* (2013) Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. *Mol Cell* 51, 310-325
- 95 Brown, J.D., *et al.* (2014) NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. *Mol Cell* 56, 219-231
- 96 Hah, N., *et al.* (2015) Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs. *Proc Natl Acad Sci U S A* 112, E297-302
- 97 Anand, P., *et al.* (2013) BET bromodomains mediate transcriptional pause release in heart failure. *Cell* 154, 569-582
- 98 Sakakibara, N., *et al.* (2013) Brd4 is displaced from HPV replication factories as they expand and amplify viral DNA. *PLoS Pathog* 9, e1003777
- 99 Li, J., *et al.* (2014) Brd4-mediated nuclear retention of the papillomavirus E2 protein contributes to its stabilization in host cells. *Viruses* 6, 319-335
- 100 Zhou, H., *et al.* (2015) Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth. *Cell Host Microbe* 17, 205-216
- 101 Boehm, D., *et al.* (2013) BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. *Cell Cycle* 12, 452-462
- 102 Li, Z., *et al.* (2013) The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. *Nucleic Acids Res* 41, 277-287
- 103 Zhu, J., *et al.* (2012) Reactivation of latent HIV-1 by inhibition of BRD4. *Cell Rep* 2, 807-816
- 104 Emadali, A., *et al.* (2013) Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. *EMBO Mol Med* 5, 1180-1195

- 105 Feng, Q., *et al.* (2014) An epigenomic approach to therapy for tamoxifen-resistant breast cancer. *Cell Res* 24, 809-819
- 106 Loosveld, M., *et al.* (2014) Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. *Oncotarget* 5, 3168-3172
- 107 Pastori, C., *et al.* (2014) BET bromodomain proteins are required for glioblastoma cell proliferation. *Epigenetics* 9, 611-620
- 108 Wong, C., *et al.* (2014) The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. *Cell Death Dis* 5, e1450
- 109 Wang, F., *et al.* (2010) Brd2 disruption in mice causes severe obesity without Type 2 diabetes. *Biochem J* 425, 71-83
- 110 Chachua, T., *et al.* (2014) Sex-specific behavioral traits in the Brd2 mouse model of juvenile myoclonic epilepsy. *Genes Brain Behav* 13, 702-712
- 111 Yavuz, E.N., *et al.* (2012) Bromodomain-containing protein 2 gene in photosensitive epilepsy. *Seizure* 21, 646-648
- 112 Boi, M., *et al.* (2015) The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. *Clin Cancer Res* 21, 1628-1638
- 113 Di Micco, R., *et al.* (2014) Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. *Cell Rep* 9, 234-247
- 114 Bolden, J.E., *et al.* (2014) Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition. *Cell Rep* 8, 1919-1929
- 115 Wienerroither, S., *et al.* (2014) Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. *Mol Cell Biol* 34, 415-427
- 116 Wang, F., *et al.* (2013) Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. *Vitam Horm* 91, 49-75
- 117 Zippo, A., *et al.* (2009) Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. *Cell* 138, 1122-1136